IL18 and COVID-19: Furthermore, IL-18, which increases in COVID-19 patients, has been described to potentiate CXCL10 expression [76, 77]; a chemokine reported to inhibit cell proliferation [78–81] and promote the death of endothelial cells [82–84]; this process being prevented by administrating a caspase inhibitor [85].